You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

78 search results for: symptoms

Most Burdensome <b>Symptoms</b> Rated by PN Patients
expert video

Most Burdensome Symptoms Rated by PN Patients

Dermatology
Dr. Chovatiya discusses the impact of pruritus on patients with PN.
View more
Beyond the Signs ​and <b>Symptoms</b>: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)
Infographic

The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)

Dermatology
A summary infographic capturing how type 2 inflammation contributes to pathological processes leading to CSU signs and symptoms.
View more
Diagnosis and Clinical Manifestations of Bullous Pemphigoid
expert video

Diagnosis and Clinical Manifestations of Bullous Pemphigoid

Dermatology
Join Dr. Meijer as he highlights the signs and symptoms of bullous pemphigoid, and the importance of accurate and prompt diagnosis.
View more
Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease
expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

Rhinology
Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.
View more
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?
expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Dermatology
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
View more
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

Rhinology
Explore the factors that contribute to the significant burden of CRSwNP on patient quality of life.
View more
Explore the Global Burden of Pediatric AD (PEDISTAD)
interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

Dermatology
This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.
View more
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

Rhinology
In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
View more
Current Treatment Landscape and Emerging Therapies
expert video

Current Treatment Landscape and Emerging Therapies

Dermatology
Dr. Lawrence F. Eichenfield reviews the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.
View more
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU
expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Dermatology
Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
View more
Skin Barrier Dysfunction in AD
expert video

Skin Barrier Dysfunction in AD

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MalaysiaChange country/region